RT Journal Article
T1 Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
A1 Conde, Esther
A1 Hernandez, Susana
A1 Martinez, Rebeca
A1 Angulo, Barbara
A1 De Castro, Javier
A1 Collazo-Lorduy, Ana
A1 Jimenez, Beatriz
A1 Muriel, Alfonso
A1 Mate, Jose Luis
A1 Moran, Teresa
A1 Aranda, Ignacio
A1 Massuti, Bartomeu
A1 Rojo, Federico
A1 Domine, Manuel
A1 Sansano, Irene
A1 Garcia, Felip
A1 Felip, Enriqueta
A1 Mancheño, Nuria
A1 Juan, Oscar
A1 Sanz, Julian
A1 Gonzalez-Larriba, Jose Luis
A1 Atienza-Cuevas, Lidia
A1 Arriola-Arellano, Esperanza
A1 Abdulkader, Ihab
A1 Garcia-Gonzalez, Jorge
A1 Camacho, Carmen
A1 Rodriguez-Abreu, Delvys
A1 Teixido, Cristina
A1 Reguart, Noemi
A1 Gonzalez-Piñeiro, Ana
A1 Lazaro-Quintela, Martin
A1 Lozano, Maria Dolores
A1 Gurpide, Alfonso
A1 Gomez-Roman, Javier
A1 Lopez-Brea, Marta
A1 Pijuan, Lara
A1 Salido, Marta
A1 Arriola, Edurne
A1 Company, Amparo
A1 Insa, Amelia
A1 Esteban-Rodriguez, Isabel
A1 Saiz, Monica
A1 Azkona, Eider
A1 Alvarez, Ramiro
A1 Artal, Angel
A1 Plaza, Maria Luz
A1 Aguiar, David
A1 Enguita, Ana Belen
A1 Benito, Amparo
A1 Paz-Ares, Luis
A1 Garrido, Pilar
A1 Lopez-Rios, Fernando
K1 FISH
K1 Immunohistochemistry
K1 Lung carcinoma
K1 Next-generation sequencing
K1 ROS1
AB The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. A total of 43 ROS1 FISH-positive and 193 ROS1 FISH-negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p  The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.
YR 2019
FD 2019-07-23
LK http://hdl.handle.net/10668/14313
UL http://hdl.handle.net/10668/14313
LA en
DS RISalud
RD Apr 11, 2025